Phase II study of 1α-hydroxyvitamin D2 in the treatment of advanced androgen-independent prostate cancer

Clinical Cancer Research

Volumn 9, Issue 11, 2003, Pages 4077-4083

  Liu, Glenn ^a,b   Wilding, George ^a   Staab, Mary Jane ^a   Horvath, Dorthea ^a   Miller, Kelly ^a   Dresen, Amy ^a   Alberti, Dona ^a   Arzoomanian, Rhoda ^a   Chappell, Rick ^a   Bailey, Howard H ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b Medical Oncology Section   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ASPARTATE AMINOTRANSFERASE; CALCIUM; DOXERCALCIFEROL; PHOSPHORUS; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; VITAMIN D DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; BLOOD SAMPLING; BONE METASTASIS; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; CYTOSTASIS; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; FATIGUE; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; MALE; MUSCLE WEAKNESS; NAUSEA; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSTATE CANCER; RASH; SURVIVAL RATE; UREMIA;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANDROGENS; ERGOCALCIFEROLS; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OSTEOCALCIN; PALLIATIVE CARE; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0141678085     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer Statistics, 2002. CA Cancer J. Clin., 52: 23-47, 2002.
2. Scher, H. I., and Kelly, W. K. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol., 11: 1566-1572, 1993.
3. Schwarz, G. G., and Hulka, B. S. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res., 10: 1307-1312, 1990.
4. Corder, E. H., Guess, H. A., Hulka, B. S., Friedman, G. D., Sadler, M., Vollmer, R. T., Lobaugh, B., Drezner, M. K., Vogelman, J. H., and Orentreich, N. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol. Biomark. Prev., 2: 467-472, 1993.
5. Ahonen, M. H., Tenkanen, L., Teppo, L., Hakama, M., and Tuohimaa, P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels. Cancer Causes Control, 11: 847-852, 2000.
6. Feldman, D., Skowronski, R. J., and Peehl, D. M. Vitamin D and prostate cancer. Adv. Exp. Med. Biol., 375: 53-63, 1995.
7. Osborn, J. L., Schwartz, G. G., Smith, D. C., Bahnson, R., Day, R., and Trump, D. L. Phase II trial of oral 1, 25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol. Oncol., 1: 195-198, 1995.
8. Slapak, C. A., Desforges, J. F., Fogaren, T., and Miller, K. B. Treatment of acute myeloid leukemia in the elderly patient with low-dose ara-c, retinoic acid, and calcitriol. Am. J. Hematol., 41: 178-183, 1992.
9. Gross, S., Stamey, T., Hancock, S., and Feldman, D. Treatment of early recurrent prostate cancer with 1, 25-dihydroxyvitamin D3 (calcitriol). J. Urol., 159: 2035-2040, 1998.
10. Shabahang, M., Buras, R. R., Davoodi, F., Schumaker, L. M., Nauta, R. J., Uskokovic, M. R., Brenner, R. V., and Evans, S. R. Growth inhibition of HT-29 human colon cancer cells by analogues of 1, 25-dihydroxyvitamin D3. Cancer Res., 54: 4057-4064, 1994.
11. Bishof, M. G., Redlich, K., Scheller, C., Chirayath, M. V., Uskokovic, M. R., Peterlik, M., and Cross, H. S. Growth inhibitory effects on human colon adneocarcinoma-derived Caco-2 cells and calcemic potential of 1α, 25-dihydroxyvitamin D3 analogs: structure-function relationships. J. Pharmacol. Exp. Ther., 275: 1254-1260, 1995.
12. Velaz-Yanguas, M. C., Kalebic, T., Maggi, M., Kappel, C. C., Letterio, J., Uskokovic, M., and Helman, L. J. 1α, 25-dihydro-16-ene-23-yne-26, 27-hexafluorocholecalciferol (Ro 24-5531) modulation of insulin-like growth factor-binding protein-3 and induction of differentiation and growth arrest in a human osteosarcoma cell line. J. Clin. Endocrinol. Metab., 81: 93-99, 1996.
13. Pirianov, G., and Colston, K. W. Interaction of vitamin D analogs with signaling pathways leading to active cell death in breast cancer cells. Steroids, 66: 309-318, 2001.
14. Schwartz, G. G., Oelert, A., Uskokovic, M. R., and Bahnson, R. R. Human prostate cancer cell lines: inhibition of proliferation by vitamin D analog. Anticancer Res., 14: 1077-1082, 1994.
15. Skowronski, R. J., Peehl, D. M., and Feldman, D. Actions of vitamin D3 analogs on human prostate cancer cell lines: comparison with 1, 25-dihydroxyvitamin D3. Endocrinology, 136: 20-26, 1995.
16. Hedlund, T. E., Moffatt, K. A., Uskokovic, R., and Miller, G. J. Three synthetic vitamin D analogs induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin. Cancer Res., 3: 1331-1338, 1997.
17. Liu, G., Oettel, K., Ripple, G., Staab, M. J., Horvath, D., Alberti, D., Arzoomanian, R., Marnocha, R., Bruskewitz, R., Mazess, R., Bishop, C., Bhattacharya, A., Bailey, H., and Wilding, G. Phase I trial of 1α-hydroxyvitamin D2 in patients with hormone refractory prostate cancer. Clin. Cancer Res., 9: 2820-2827, 2002.
18. See, W. A., Wirth, M. P., MCLeod, D. G., Iversen, P., Klimberg, I., Gleason, D., Chodak, G., Montie, J., Tyrrell, C., Wallace, D., Delaere, P. J., Vaage, S., Tammela, T., Lukkarinen, O., Persson, B., Carroll, K., and Kolvenbag, G. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J. Urol., 168: 429-435, 2002.
19. Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., and Trump, D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. NEJM, 341: 1781-1788, 1999.
20. Holmberg, L., Bill-Axelson, A., Helgesen, F., Salo, J., Folmerz, P., Haggman, M., Andersson, S., Spangberg, A., Busch, C., Nordling, S., Palmgren, J., Adami, H., Johansson, J., and Norlen, B. J. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. NEJM, 347: 781-789, 2002.
21. Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., and Murphy, K. C. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomization trial with palliative endpoints. J. Clin. Oncol., 14: 1756-1764, 1996.
22. Savarese, D. M., Halabi, S., Hars, V., Akerley, W. L., Taplin, M. E., Godley, P. A., Hussain, A., Small, E. J., and Vogelzang, N. J. Phase H study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J. Clin. Oncol., 19: 2509 -2516, 2001.
23. Smaletz, O., Scher, H. I., Small, E. J., Verbel, D. A., McMillan, A., Regan, K., Kelly, W. K., and Kattan, M. W. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J. Clin. Oncol., 20: 3972-3982, 2002.
24. Wikstrom, P., Damber, J., and Bergh, A. Role of transforming growth factor-beta1 in prostate cancer. Microscopy Research Technique, 52: 411-419, 2001.
25. Heberden, C., Denis, I., Pointillart, A., and Mercier, T. TGF-beta and calcitriol. Gen. Pharmacol., 30: 145-151, 1998.
26. Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., Hussain, M., Kaplan, R., Myers, C., Oh, W., Petrylak, D. P., Reed, E., Roth, B., Sartor, O., Scher, H., Simons, J., Sinibaldi, V., Small, E. J., Smikth, M. R., Trump, D. L., Vallmer, R., and Wilding, G. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol., 17: 3461-3467, 1999.
27. Amhed, S., Johnson, C. S., Rueger, R. M., and Trump, D. L. Calcitriol (1, 25 dihydroxycholecalciferol) potentiates activity of mitoxantrone/ dexamethasone in an androgen independent prostate cancer model. J. Urol., 168: 756-761, 2002.